$RDGT

Ridgetech Inc. (RDGT): Financial results for FY2026

Ridgetech Inc. (RDGT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results HANGZHOU, China, July 31, 2026 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) (“Ridgetech” or the “Company”), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced

Original reporting
Published Jul 31, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 7:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RDGT
Bearish
medium confidence
Mentioned
$RDGT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$RDGTBearishMed
01

Why it matters

The earnings release provides the first public view of post‑acquisition performance, showing mixed results.

02

Market read

RDGT's FY2026 results signal operational transition risks and opportunities for China pharma distributors.

03

What to watch

Improved cash balance and expanded digital footprint could offset short‑term earnings weakness.

Relevance 7/10Novelty 7/10Timing: post-market July 31 2026 release

Background

Ridgetech transitioned to a wholesale‑focused model, acquiring Allright and divesting retail stores.

Company-level read

Ticker impact

$RDGTBearishMedium confidence
Context

FY2026 earnings show 10.2% revenue growth to $132.2M but a net loss of $1.25M versus prior year profit.

Expected impact

Potential short-term downside pressure with limited upside unless guidance improves.

Evidence & confidence

Loss reversal and modest revenue growth suggest weak earnings momentum; investors may sell.

Market effects

Highlights shift toward online wholesale in Chinese pharma distribution, offline decline.

May influence sentiment on China healthcare logistics and related peers.

Limited global impact; primarily relevant to China‑focused investors.

Counterpoint

Loss could be temporary as online platform scales; revenue growth may support a rebound.

Key entities

  • Ridgetech Inc.

    Nasdaq‑listed Chinese wholesale distributor of pharmaceutical products.

  • Allright (Hangzhou) Internet Technology Co. Ltd

    Online wholesale platform acquired by Ridgetech.

Related articles

$RDGTMed

Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results

Ridgetech, Inc. (Nasdaq: RDGT) reported fiscal year 2026 results for the year ended March 31, 2026. Revenue rose 10.2% to $132.16 million, driven by a full year of Allright’s online platform after its Feb. 28, 2025 acquisition. Gross profit increased 23.8% to $4.75 million, but net loss was $1.25 million versus net income $10.20 million a year earlier.

$APLDMedAI 8/10

Applied Digital Corp (APLD) (Q1 2027) Earnings Call Highlights: Revenue Soars 322%

Applied Digital Corp (APLD) reported Q1 2027 revenue growth of 322% but a net loss of $221M. The company has $6.4B in debt and high stock-based compensation expenses. CEO Wes Cummins highlighted strong demand, premium pricing for leases, and expansion plans in Finland and North Dakota. The company is also focusing on mitigating supply chain constraints and adapting to changing customer workloads.

$005930.KSHighAI 9/10

Why is Samsung Electronics stock falling today?

Samsung Electronics (005930) fell 1.5% to ₩264,500 after reporting a Q3 2026 operating profit of 107.4 trillion won, slightly below analyst expectations. The drop coincided with semiconductor ETF rebalancing and options expiry. Foreign and institutional investors sold shares, outweighing retail buying interest. The broader KOSPI index also declined nearly 2%.

$LEVIHighAI 8/10

Levi Strauss Q3 Income Drops

Levi Strauss (LEVI) reported Q3 net income of $168.6M ($0.43 EPS), down from $218.1M ($0.55 EPS) last year. Adjusted earnings were $188.9M ($0.48 EPS). Revenue rose 4.3% to $1.609B. Full-year EPS guidance is $1.54-$1.56, adjusted for foreign exchange.